Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
176
resultados
Última actualización
26/02/2026 [07:34:00]
Resultados 50 a 75 de 176
Resumen de: WO2025244478A1
The present invention relates to a novel microorganism and a use thereof for preventing, alleviating, or treating intestinal diseases. The strain according to one embodiment has effects of inhibiting intestinal atrophy and reducing bloody stools, and thus is useful for the prevention, amelioration, or treatment of intestinal diseases. In addition, since the strain is significantly reduced in the patient group, the strain can be used for early diagnosis of intestinal diseases or selection of a risk group.
Resumen de: WO2025244988A1
Disclosed are methods of characterizing, diagnosing, monitoring, and/or treating an individual with Crohn's Disease (CD) comprising detecting, in a biological sample obtained from the individual, a plurality of biomarkers. The biomarkers may be used for one or more of predicting remission of CD in an individual, determining longitudinal assessment of response to a biologic therapy, predicting or determining response status of the individual to an anti-tumor necrosis factor (TNF) therapy. Further disclosed are systems and compositions for use with the disclosed methods.
Resumen de: WO2025245006A1
Provided herein arc systems and methods for testing exhaled breath from a subject (e.g., suspected of having inflammatory bowel disease, IBD) to determine the level of at least one volatile organic compound (e.g., 1 or 5 or 8 compounds). In certain embodiments, one receives test results, such as an elevated or decreased level of a particular volatile organic compound, and this is used to determine if a subject has IBD or needs treatment with an IBD treating agent. In other embodiments, the subject is treated with an IBD treating agent, and optionally tested again to monitor treatment (e.g., tested over days, weeks, or months). In other embodiments, the subject is determined to have moderate or severe IBD, or mild or no IBD.
Resumen de: MX2025011513A
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Resumen de: US2025237665A1
A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohn's disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohn's disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: CN120983481A
The invention relates to an application of a Blautia pseudococcoides bacterium in preparation of a medicine for treating ulcerative colitis, in particular to an application of the Blautia pseudococcoides bacterium in preparation of a medicine for treating ulcerative colitis. Specifically, the invention provides an application of the Blauria pseudococcoides bacterium in preparation of a medicine for preventing and/or treating the inflammatory bowel disease, and the preservation number of the Blauria pseudococcoides bacterium is DSM26115. Furthermore, the present invention relates to a composition for diagnosing inflammatory bowel disease comprising an agent for measuring the level of enteric microorganisms, a kit comprising the composition, and a method for diagnosing inflammatory bowel disease comprising a step of measuring the level of enteric microorganisms.
Resumen de: JP2025171299A
To provide: a technique that can predict the prognosis of inflammatory bowel disease, can contribute to verifying treatment effects at that point in time, imposes less physical burden, and has high accuracy (low likelihood of missing individuals at risk of worsening disease); and a technique that can contribute to diagnosing inflammatory bowel disease, imposes less physical burden, and enables inexpensive and rapid testing of the likelihood of contracting inflammatory bowel disease.SOLUTION: A method for predicting the prognosis of inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject. A method for testing inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject.SELECTED DRAWING: Figure 6
Resumen de: AU2024265914A1
The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.
Resumen de: WO2025240975A1
Pulmonary arterial hypertension (PAH) exhibits an obliterative vasculopathy where complex, integrated pathobiological signaling pathways drive vascular remodeling. In PAH, the arteriopathy includes numerous endophenotypes that occur to differing extents across patients. Variability in the proteomic and genetic profile is observed, causing phenotypic heterogeneity and inconsistent clinical responses to drug therapies. We have used network medicine to discover modifiable therapeutic targets in PAH by generating patient-specific protein-protein interaction (PPI) networks to unmask molecular interactions that identify and distinguish groups of individual patients with the same clinical phenotype. This allows personalized clinical phenotyping in PAH in those patient groups. The findings here also clarify the relationship between PAH genetic risk and pathobiology on an individual patient level, and inform treatment rationales and personalized drug selection using the PPI networks. Overall, findings from this project will advance precision medicine in PAH with direct relevance to the clinical management of patients.
Resumen de: CN118581208A
The invention provides a marker for diagnosing systemic inflammation and application, the marker comprises ADGRE3mRNA or ADGRE3 protein, or ADGRE3mRNA fragment and ADGRE3 protein fragment, the marker content in samples of systemic inflammation patients and healthy people has significant difference, clinical verification shows that the marker is high in diagnosis sensitivity and specificity, and the marker can be applied to diagnosis of systemic inflammation. Therefore, systemic inflammation can be accurately diagnosed by detecting the transcription level of ADGRE3 mRNA or the expression level of ADGRE3 protein in an individual sample. Compared with an existing inflammation marker, the ADGRE3 mRNA and the ADGRE3 protein have higher sensitivity and specificity in the aspect of diagnosis of systemic inflammation.
Resumen de: TW202544255A
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Resumen de: MX2025011513A
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Resumen de: CN120945033A
The invention discloses a tissue resident bacterium marker for identifying normal colorectal tissue, polyp and intestinal cancer and application of the tissue resident bacterium marker. According to the present invention, the tissue resident bacterium markers comprise Pseudomonas, Pigmentiphaga, Fusobacteria, Parabacteroides, Bacteroides, Collinsella and Parvimonas, and can be used to reflect the biological specificity of patients, and the biological specificity of the patients can be represented by the tissue resident bacterium markers, such that the biological specificity of the patients can be represented by the tissue resident bacterium markers, and the biological specificity of the patients can be represented by the tissue resident bacterium markers, such that the biological specificity of the patients can be represented by the tissue resident bacterium markers, and the biological specificity of the patients can be represented by the tissue resident bacterium markers; according to the present invention, with the combination model of the six bacteria such as Pseudomonas, Pigmentiphaga, Fusobacteria, Parabacteroides, Bacteroides and Collinsella, the normal tissue and polyp of the colorectum can be accurately identified, and the accuracy is improved by 12.5% compared with the accuracy of the existing non-invasive screening method; the polyp and the intestinal cancer can be more accurately identified by a combined model of four bacteria, namely, Pseudomonas, Pigmentiphaga, F
Resumen de: CN120958143A
The present invention provides compositions and methods for diagnosing disease, assessing disease activity, monitoring mucosal healing, and predicting therapeutic response using fecal-derived eukaryotic nucleic acid biomarkers. The biomarkers can be used by practitioners for better diagnosis, management and treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: WO2025232867A1
A method for detecting anxiety and/or depression metabolic and microbiome markers in a patient with irritable bowel syndrome (IBS) is provided. The method begins with obtaining a serum sample and a fecal sample from the patient. Both samples are processed to extract a gut metagenome, including a bacteriome, a mycobiome, and a virome of the patient, and metabolic features. A classifier is utilized to detect whether a marker set of microbial species and metabolites for depression and anxiety is present in the gut metagenome and the metabolic features.
Resumen de: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: CN120927854A
The invention discloses an exhaled gas VOC (volatile organic compound) marker for detecting inflammatory bowel diseases and a detection system thereof. The marker is a combination of one or more of the following components: methyl propyl sulfide, propionaldehyde, cyclohexanone, allyl methyl sulfide, octanal, 2-pentanone, phenol, butyric acid, propionic acid and 3-methylheptane. The detection system comprises an exhaled air sampling module, a sample preprocessing module, a detection analysis module and a data analysis module. The marker provided by the invention has the advantages of high specificity and good stability, can realize accurate noninvasive diagnosis of IBD, and can assist in realizing early screening and dynamic monitoring in a clinical environment.
Resumen de: CN120905354A
The invention relates to the field of genetic typing, and discloses a plectropomus leopardus generic genome typing method based on low-cost DNA extraction, which comprises the following steps: carrying out DNA sampling extraction on plectropomus leopardus to construct a re-sequencing library, processing DNA data of all high-depth groups in the re-sequencing library by using Shape software, constructing a haplotype database, and carrying out genotyping on the haplotype database. And performing genotype filling on the low-depth sequencing individuals to obtain haplotypes and genotypes of the low-depth sequencing individuals, and establishing a generic genome IBD cluster typing technology. And finally, generating an individual-level report of the target plectropomus leopardus. According to the invention, a lossless, simple and low-cost DNA extraction technology for the plectropomus leopardus can be established, large-scale sample application is realized, and the purpose of generic genome typing of the plectropomus leopardus is realized.
Resumen de: CN120904133A
The invention provides an HClO activated diagnosis and treatment fluorescent prodrug as well as a synthesis method and application thereof, and the fluorescent prodrug has the Chinese name of 5-(3, 7-bis (dimethylamino)-10H-phenothiazine-10-formamido)-2-hydroxybenzoic acid. The invention also provides a synthesis method of the fluorescent prodrug. The fluorescent prodrug constructed by the invention can be specifically and rapidly activated by HClO (lt, 5min), releases near-infrared fluorophore methylene blue and a first-line drug 5-aminosalicylic acid for inflammatory bowel diseases, and has excellent specificity and sensitivity. In addition, response products are analyzed through high-resolution mass spectrometry, effective release of methylene blue and 5-aminosalicylic acid is proved, and feasibility of the compound serving as a prodrug for diagnosis and treatment of the inflammatory bowel disease is shown. According to the diagnosis and treatment fluorescent prodrug, non-invasive fluorescence imaging and treatment components are combined, and reasonable design and application of diagnosis and treatment integrated molecules are achieved.
Resumen de: WO2025230979A1
Provided herein are, inter alia, agents (e.g., RNAi agents, dsRNA agents) comprising a sense strand and an antisense strand targeting TNFAIP3 (e.g., hTNFAIP3); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the RNA agents (e.g., RNAi agents, dsRNA agents) including, e.g., methods of inhibiting or decreasing TNFAIP3 expression (e.g., mRNA expression), methods of treating TNFAIP3 associated diseases, and methods of treating proinflammatory (e.g., autoimmune) diseases (e.g., inflammatory bowel disease); and cancer.
Resumen de: US2025340627A1
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
Resumen de: WO2025229605A1
New and useful computer-implemented methods; methods of identifying markers associated with enteropathies; methods of determining the level of severity of an enteropathy; and determining a treatment for an enteropathy; are disclosed. In addition, the present disclosure provides methods of identifying a biological response to one or more treatments for an enteropathy, and whether a given treatment to an enteropathy results in a therapeutic or adverse effect, as determined in a spatiotemporal manner throughout the entirety of the small bowel, or a region of interest therein.
Resumen de: AU2024236253A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: MX2025011513A
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Nº publicación: IL323177A 01/11/2025
Solicitante:
NOGRA PHARMA LTD [IE]
BELLINVIA SALVATORE [IE]
VITI FRANCESCA [IE]
MCNULTY MARIE [IE]
DEMARTIS SALVATORE [IE]
NOGRA PHARMA LIMITED,
BELLINVIA Salvatore,
VITI Francesca,
MCNULTY Marie,
DEMARTIS Salvatore
Resumen de: MX2025011513A
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
BOPI
Sede Electrónica
